Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
GBD Chronic Kidney Disease Collaboration.
Lancet. 2020 Feb 29;395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3. Epub 2020 Feb 13.
Hyperuricemia and its related diseases: mechanisms and advances in therapy.
Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, Pang Y, Zhang C, Zhong Z, Gao J.
Signal Transduct Target Ther. 2024 Aug 28;9(1):212. doi: 10.1038/s41392-024-01916-y.
The Gut Microbiome in Hyperuricemia and Gout.
Terkeltaub R, Dodd D.
Arthritis Rheumatol. 2025 Aug;77(8):955-965. doi: 10.1002/art.43118. Epub 2025 Feb 13.
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group.
Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9.
Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease.
Wang Y, Dalbeth N, Terkeltaub R, Zhang Y, Li X, Zeng C, Lei G, Wei J.
JAMA Intern Med. 2025 Jan 1;185(1):74-82. doi: 10.1001/jamainternmed.2024.6212.
Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights.
Mei Y, Dong B, Geng Z, Xu L.
Front Endocrinol (Lausanne). 2022 Jul 14;13:911968. doi: 10.3389/fendo.2022.911968. eCollection 2022.
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.
Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.
Managing Gout in the Patient with Renal Impairment.
Pascual E, Sivera F, Andrés M.
Drugs Aging. 2018 Apr;35(4):263-273. doi: 10.1007/s40266-018-0517-7.
Pipeline Therapies for Gout.
Yip K, Braverman G, Yue L, Fields T.
Curr Rheumatol Rep. 2024 Mar;26(3):69-80. doi: 10.1007/s11926-023-01128-3. Epub 2023 Dec 22.
Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment.
Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L.
Arthritis Rheumatol. 2016 Aug;68(8):2035-43. doi: 10.1002/art.39654.
